Researchers identified 2,314 genetic changes in polyps and adjacent mucosa, revealing potential drug targets for colorectal cancer prevention. The study also found similarities between premalignant and cancerous tissue, suggesting that polyps with more genetic changes may be more likely to develop into CRC.
Researchers found more than half of the genes studied showed sex-biased signatures in certain cancer types, revealing two sex-effect groups associated with distinct incidence and mortality profiles. These findings lay a critical foundation for precision cancer medicine that is sex-specific.
Researchers identified three subtypes of ACC with distinct clinical outcomes and molecular alterations. The study also found novel ACC driver genes and suggests that inhibiting whole genome doubling could slow tumor growth. These findings may inform therapeutic decisions and lead to significant advances in patient outcomes.
A study by researchers at the University of Texas M. D. Anderson Cancer Center found that gene therapy may be able to reverse cancer-related nerve pain. The treatment, which involves transferring a gene called KCC2 into the spinal canal, restored chloride levels and eliminated pain hypersensitivity in rats.
A new study published in Cell Reports identifies microRNA molecule miR551b as a promising candidate biomarker and therapeutic target for treating ovarian cancers. The research found that targeting miR551b expression could block STAT3 activity, offering potential for treating the most common and deadly form of ovarian cancer.
Researchers discovered TJP1's role in identifying patients most likely to benefit from proteasome inhibitors, with low TJP1 levels associated with resistance. The study provides a rationale for using TJP1 as a biomarker for personalized treatment approaches.
Researchers developed Monovar to analyze multiple single cells, detecting subtle DNA changes that can inform personalized medicine and cancer care. The method shows promise for diagnosing and treating various diseases, including pre-natal genetic diagnosis.
A study at the University of Texas M. D. Anderson Cancer Center found that normal liver cells metabolize dietary fructose differently than cancerous cells, revealing a potential diagnostic marker for liver cancer. The researchers discovered a gene called KHK that is expressed differently in healthy and tumor tissues.
A phase I study of LOXO-101 demonstrated efficacy in reducing tumors in six patients with TRK fusion-positive cancers, including sarcoma, thyroid, and non-small cell lung. The study showed significant tumor regression in all six patients, with one patient experiencing a 17% tumor reduction.
Researchers at MD Anderson Cancer Center reported encouraging correlations between immunologic biomarkers and responses to treatment with nivolumab in the first-ever phase II clinical trial for metastatic squamous cell carcinoma of the anal canal. Five patients treated with nivolumab experienced significant tumor size reductions.
A study published by the University of Texas M.D. Anderson Cancer Center found a link between obesity and kidney cancer recurrence, with leptin receptors playing a key role in tumor formation. The research suggests that obesity may also impact prognosis for patients with renal cell carcinoma.
A study from MD Anderson Cancer Center reveals a strong association between hepatitis C and certain head and neck cancers, such as oropharyngeal and nonoropharyngeal cancers. The findings have significant implications for screening and treatment of both conditions.
A new breast cancer staging system, Neo-Bioscore, incorporates HER2 status to provide more precise prognostic stratification of all breast cancer subtypes. The system improves prognosis and identifies patients in greatest need of additional therapy.
Physician-scientists Ethan Dmitrovsky and Waun Ki Hong recognized for their efforts in cancer prevention and control. Dmitrovsky's work on retinoids has led to a significant impact on leukemia treatment, while Hong's research in cancer chemoprevention and personalized therapies has advanced the field.
A new study from the University of Texas M. D. Anderson Cancer Center found that neurofeedback significantly reduces chronic pain and improves quality of life in cancer patients with chemotherapy-induced neuropathy. The treatment, which uses electroencephalogram biofeedback to modify brain activity, showed a 73% improvement rate in pai...
Researchers found PGK1 plays a key role in coordinating cellular processes for cancer metabolism and brain tumor formation. The enzyme promotes energy production through the Warburg effect, leading to rapid cancer growth.
A study by the University of Texas M.D. Anderson Cancer Center reveals that adult stem cells in the prostate basal cell layer express genes similar to those found in deadly prostate cancer, offering a potential new line of treatment for highly aggressive and therapy-resistant forms.
The University of Texas MD Anderson Cancer Center received $14 million in CPRIT research funding to recruit three cancer scientists, including two senior researchers and a tenure-track faculty member. This funding supports the institution's goal of attracting top research talent to advance cancer research.
A recent clinical study found that ONC201 caused cell death in various tumor types, even when the p53 protein was mutated or deleted. The drug has shown promise in treating hematological malignancies, including leukemia and lymphoma patients, with clinical trials recently initiated.
Researchers at MD Anderson Cancer Center proposed a new staging system for HPV-related oropharyngeal cancer, which better separates patients with different survival rates. The new groupings were proven to have greater predictive power than the current system, particularly in identifying stage III disease with a high risk of death.
Researchers will compare surgery and active surveillance in women with low-grade DCIS, evaluating quality of life and psychosocial outcomes. The four-year study aims to answer whether invasive surgery is necessary for non-fatal disease.
A multi-center study identified distinct molecular and clinical features in diffuse glioma patients, shedding light on disease progression. The findings may lead to improved treatment outcomes by enabling precise prediction of tumor growth and response to therapy.
A new procedure, Targeted Axillary Dissection (TAD), reduces need for invasive surgery in select patients with axillary metastasis. TAD involves removing sentinel lymph nodes and additional cancerous lymph nodes found during diagnosis, improving staging accuracy and reducing complications.
A study published in Nature Immunology identified Trabid, a protein regulator, as a key component in regulating interleukin genes and promoting autoimmune inflammation in multiple sclerosis patients. This finding suggests that Trabid may be a potential therapeutic target for treating inflammatory diseases such as MS.
A new study suggests that combining PARP inhibitors with c-MET inhibitors may improve treatment outcomes for patients with breast cancer and high c-MET expression levels.
A multi-institutional international study has revealed new information about the interaction between long non-coding RNAs and HIF-1 signaling pathways in triple-negative breast cancer. The study identifies four previously unknown phosphorylation sites, which predict a worse outcome for TNBC patients, suggesting that these sites could s...
A recent study at MD Anderson Cancer Center found that dietary sugar, particularly fructose, can increase the risk of breast cancer tumors and lung metastasis in mice. The research suggests that high sugar intake activates an inflammatory pathway called 12-LOX, leading to increased tumor growth and spread.
Researchers at MD Anderson Cancer Center identified myeloid-derived suppressor cells (MDSCs) as a key player in advanced prostate cancer progression. Depletion of MDSCs and blocking specific signaling pathways showed promise in suppressing tumor growth, paving the way for potential therapeutic opportunities.
Researchers at MD Anderson Cancer Center have developed a new liquid biopsy technique that can analyze tumor genes from blood samples using exosomes, providing a non-invasive alternative to traditional biopsies. The approach has the potential to improve prognosis, guide targeted therapy, and monitor treatment progress.
A new study from MD Anderson Cancer Center found that delaying chemotherapy after surgery increases the risk of death for breast cancer patients, particularly those with triple-negative breast cancer. Patients who start treatment within 90 days have a lower risk of death compared to those who delay it.
A new study from the University of Texas MD Anderson Cancer Center found that mastectomy plus reconstruction has the highest rate of complications and complication-related costs among guideline-concordant therapies for early breast cancer. The study also revealed that this treatment option is the most expensive in younger patients, wit...
A Phase I study combining natural killer cells with high-dose chemotherapy and stem cell transplantation showed promising results in treating multiple myeloma. The treatment resulted in no toxicity or graft-versus-host disease, offering a potential new approach for patients.
Researchers found that losing CD73 enzyme promotes tumor growth and progression in endometrial cancer by disrupting adenosine signaling, which normally regulates tissue function. The study provides new insights into the role of CD73 in cancer development.
A multi-center study found ibrutinib to be more effective than chlorambucil in treating CLL, with a 97.8% overall survival rate after two years compared to 85.3%. Ibrutinib also improves hemoglobin and platelet levels.
A comprehensive study led by MD Anderson Cancer Center researchers found complete surgical excision of the implant and surrounding capsule to be the most effective treatment approach for BI-ALCL, with significant improvements in event-free survival and overall survival compared to radiation therapy and chemotherapy.
Researchers found p53 blocks PDL1 protein, which halts immune attack on lung cancer cells. High levels of p53 and miR-34a increase survival rates in patients with lung cancer.
A study at MD Anderson Cancer Center reveals that increased methylation of epidermal growth factor receptors (EGFR) leads to resistance to cetuximab antibody therapy, resulting in poorer clinical outcomes and higher recurrence rates. The study also found that expression of methylation-defective EGFR reduces tumor growth in mice.
A study at MD Anderson Cancer Center found that suppressing epithelial-to-mesenchymal transition (EMT) in combination with gemcitabine may boost the drug's effectiveness against pancreatic cancer. EMT suppression leads to impaired sensitivity to chemotherapy, causing poor prognosis and metastasis.
A genetic biomarker called loss of heterozygosity (LOH) predicts which patients with premalignant mouth lesions are at highest risk of developing oral cancer. The study found that LOH-positive patients had a three-year cancer-free survival rate of 74% compared to 87% for LOH-negative patients.
A new study from MD Anderson Cancer Center finds that high-temperature cooking of meat, particularly barbecuing and pan-frying, increases the risk of renal cell carcinoma. Individuals with certain genetic mutations are more susceptible to this risk, highlighting the importance of reducing meat consumption, especially at high temperatures.
Researchers found that tumor suppressor protein PTEN is lost in brain cancer cells but restored once they migrate to other organs. This reversible loss enables brain metastases growth and protects against cell death.
A study published by the University of Texas M. D. Anderson Cancer Center found that intensity modulated radiation therapy (IMRT) reduced severe pneumonitis and improved chemotherapy tolerance in patients with locally advanced non-small cell lung cancer compared to conventional radiation therapy.
A study led by University of Texas M. D. Anderson Cancer Center researchers identified EphB4 as a trigger for tumor growth via STAT3 protein regulation, linking cancer anemia treatment to tumor progression.
Researchers have discovered a new approach to understanding cancer mechanisms, biomarkers, and treatments using RNA editing events. The study, published in Cancer Cell, found that specific RNA editing processes could selectively affect drug sensitivity and may lead to the development of targeted therapies.
The study found that everolimus improved progression-free survival by 52% and increased median progression-free survival by over seven months in patients with advanced, nonfunctional neuroendocrine tumors. The treatment was well-tolerated, with common side effects including aphthous ulceration, rash, diarrhea, fatigue, and infections.
Researchers at the University of Texas MD Anderson Cancer Center demonstrated a significant median overall survival benefit with nivolumab, increasing it to 25 months compared to 19.6 months for everolimus. The study also showed a higher objective response rate and fewer treatment-related adverse events with nivolumab.
A protein-coding gene called hnRNP K has been identified as a potential target for treating acute myeloid leukemia. The study found that expression of hnRNP K is significantly reduced in AML patients who carry a specific genetic deletion, suggesting it acts as a tumor suppressor.
Researchers found that generic heart medications, specifically nonselective beta-blockers, significantly improved overall survival among ovarian cancer patients. This is attributed to the ability of these drugs to block stress pathways involved in tumor growth and spread, with further research needed to explore their potential benefits.
Scientists have discovered a cytokine called MIF that regulates EGFR activation in the tumor microenvironment, promoting tumor progression. The findings could lead to new approaches in treating tumors by intervening in this self-regulating loop.
A study at the University of Texas MD Anderson Cancer Center found that CSN6 is overexpressed in colorectal cancer tissue samples, leading to poor survival rates. The biomarker's deregulation can lead to cancer development through cellular signaling pathways.